Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Cell Sci ; 129(12): 2394-406, 2016 06 15.
Artigo em Inglês | MEDLINE | ID: mdl-27142834

RESUMO

FXYD5 (also known as dysadherin), a regulatory subunit of the Na,K-ATPase, impairs intercellular adhesion by a poorly understood mechanism. Here, we determined whether FXYD5 disrupts the trans-dimerization of Na,K-ATPase molecules located in neighboring cells. Mutagenesis of the Na,K-ATPase ß1 subunit identified four conserved residues, including Y199, that are crucial for the intercellular Na,K-ATPase trans-dimerization and adhesion. Modulation of expression of FXYD5 or of the ß1 subunit with intact or mutated ß1-ß1 binding sites demonstrated that the anti-adhesive effect of FXYD5 depends on the presence of Y199 in the ß1 subunit. Immunodetection of the plasma membrane FXYD5 was prevented by the presence of O-glycans. Partial FXYD5 deglycosylation enabled antibody binding and showed that the protein level and the degree of O-glycosylation were greater in cancer than in normal cells. FXYD5-induced impairment of adhesion was abolished by both genetic and pharmacological inhibition of FXYD5 O-glycosylation. Therefore, the extracellular O-glycosylated domain of FXYD5 impairs adhesion by interfering with intercellular ß1-ß1 interactions, suggesting that the ratio between FXYD5 and α1-ß1 heterodimer determines whether the Na,K-ATPase acts as a positive or negative regulator of intercellular adhesion.


Assuntos
Glicoproteínas de Membrana/metabolismo , Proteínas de Neoplasias/metabolismo , Multimerização Proteica , Subunidades Proteicas/metabolismo , ATPase Trocadora de Sódio-Potássio/metabolismo , Células A549 , Aminoácidos/metabolismo , Animais , Especificidade de Anticorpos , Adesão Celular , Linhagem Celular Tumoral , Membrana Celular/metabolismo , Cães , Células Epiteliais/metabolismo , Técnicas de Silenciamento de Genes , Glicosilação , Células HEK293 , Humanos , Canais Iônicos , Células Madin Darby de Rim Canino , Camundongos , Proteínas dos Microfilamentos , Ligação Proteica , Subunidades Proteicas/química , Ratos , ATPase Trocadora de Sódio-Potássio/química
2.
J Biol Chem ; 286(43): 37067-76, 2011 Oct 28.
Artigo em Inglês | MEDLINE | ID: mdl-21903582

RESUMO

Elevated CO(2) concentrations (hypercapnia) occur in patients with severe lung diseases. Here, we provide evidence that high CO(2) levels decrease O(2) consumption and ATP production and impair cell proliferation independently of acidosis and hypoxia in fibroblasts (N12) and alveolar epithelial cells (A549). Cells exposed to elevated CO(2) died in galactose medium as well as when glucose-6-phosphate isomerase was knocked down, suggesting mitochondrial dysfunction. High CO(2) levels led to increased levels of microRNA-183 (miR-183), which in turn decreased expression of IDH2 (isocitrate dehydrogenase 2). The high CO(2)-induced decrease in cell proliferation was rescued by α-ketoglutarate and overexpression of IDH2, whereas proliferation decreased in normocapnic cells transfected with siRNA for IDH2. Also, overexpression of miR-183 decreased IDH2 (mRNA and protein) as well as cell proliferation under normocapnic conditions, whereas inhibition of miR-183 rescued the normal proliferation phenotype in cells exposed to elevated levels of CO(2). Accordingly, we provide evidence that high CO(2) induces miR-183, which down-regulates IDH2, thus impairing mitochondrial function and cell proliferation. These results are of relevance to patients with hypercapnia such as those with chronic obstructive pulmonary disease, asthma, cystic fibrosis, bronchopulmonary dysplasia, and muscular dystrophies.


Assuntos
Dióxido de Carbono/farmacologia , Proliferação de Células/efeitos dos fármacos , Hipercapnia/metabolismo , Mitocôndrias/metabolismo , Regulação para Cima/efeitos dos fármacos , Linhagem Celular , Humanos , Hipercapnia/patologia , Isocitrato Desidrogenase/metabolismo , Ácidos Cetoglutáricos/metabolismo , Pneumopatias/metabolismo , MicroRNAs/metabolismo , Mitocôndrias/patologia , Distrofias Musculares/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...